Menu Close Menu

SOCIAL

POSTS/QUERIES UNDER SOCIAL
Air pollutants and progression of emphysema in a large, community-base multi-ethnic cohort(homes of study participants)

Air Pollutants And Progression Of Emphysema In A Large, Community-base Multi-ethnic Cohort(homes Of Study Participants)

1

0

0

  • Posted On : 19-Aug-2019
Emphysema was measured from CT scans that identify holes in the small air sacs of the participants' lungs, and lung function tests, which measure the speed and amount of air breathed in and out. "Rates of chronic lung disease in this country are going up and increasingly it is recognized that this disease occurs in nonsmokers," said Kaufman, also a professor of internal medicine and a physician at UW School of Medicine. "We really need to understand what's causing chronic lung disease, and it appears that air pollution exposures that are common and hard to avoid might be a major contributor." "This study adds to growing evidence of a link between air pollution and emphysema. A better understanding of the impact of pollutants on the lung could lead to more effective ways of preventing and treating this devastating disease," The authors developed novel and accurate exposure assessment methods for air pollution levels at the homes of study participants, collecting detailed measurement of exposures over years in these metropolitan regions, and measurements at the homes of many of the participants. This work in the MESA Air study was led at the University of Washington. While most of the airborne pollutants are in decline because of successful efforts to reduce them, ozone has been increasing, the study found. Ground-level ozone is mostly produced when ultraviolet light reacts with pollutants from fossil fuels. https://www.sciencedaily.com/releases/2019/08/190813180833.htm https://www.usnews.com/news/cities/slideshows/the-10-us-cities-with-the-most-ozone-pollution?onepage

SOCIAL

Big Pharma - R&D vs financial engineering

Big Pharma - R&D Vs Financial Engineering

2

0

0

  • Posted On : 04-Aug-2019
For all its commercial and scientific success, Humira offers a sharply focused lens on what’s wrong with the legacy drug industry at large. AbbVie’s convoluted web of patents and other strategies will keep would-be competitors off the U.S. market until 2023. That means fewer choices—and higher costs—for consumers who might otherwise pursue cheaper options. This is a consequence of the “blockbuster” drug model, wherein a company relies on one or two key products that ring in billions annually. Hundreds of millions go to marketing and legal-fortress building, while innovation and scientific discovery—ostensibly the beating heart of the biopharmaceutical industry—is often imported from the outside: in-licensed, for instance, from leaner biotechs that actually do place an emphasis on innovation. So, you might wonder, what’s not to like about a medicine that helps millions of people suffering from serious and painful conditions and that has made its owners billions of dollars in the process? Isn’t that what the pharmaceutical industry is supposed to do? The answer, like so many aspects of the drug industry, lies in the litany of side effects that are spelled out in the fine print. For the Humira tale has a dark side too—one that’s reflected in many billions of dollars in unnecessary drug costs for consumers and in stymied competition in a critical area of modern drug development. As much as it might look like the quintessential example of scientific innovation and marketing success, the story of how Humira became the world’s bestselling drug is a case study of an industry in slow-motion failure—of a corporate model that is increasingly forsaking investing in research and discovery in favor of purchasing it (at a premium) from the outside. That model is driving up costs for everybody—patients, government payers, insurers, and, yes, even drug company shareholders. https://fortune.com/longform/abbvie-humira-drug-costs-innovation/?utm_source=The+Sunday+Long+Read+subscribers&utm_campaign=5311bbe84e-EMAIL_CAMPAIGN_2019_07_20_03_19&utm_medium=email&utm_term=0_67e6e8a504-5311bbe84e-267473789

SOCIAL

© 2017 Public Health Literacy Powered By

Loading...